To continue reading this content, please enable JavaScript in your browser settings and refresh this page. "Until just a decade ago, immuno-oncology was a dream. The ...
NANTES, France, April 12, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE) today announces a new organization within its Board of Directors with the appointment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results